Treatment persistence and compliance with a combination of calcium and vitamin D

Climacteric

Volumn 13, Issue 6, 2010, Pages 578-584

  Castelo Branco, C ^a   Cortes X ^b   Ferrer, M ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c ADKNOMA Health Research SL   (Spain)

Author keywords

CALCIUM AND VITAMIN D COMBINATION; PERSISTENCE AND COMPLIANCE; REASONS FOR TREATMENT DISCONTINUATION

Indexed keywords

CALCIUM; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FATIGUE; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR;

AGED; BODY MASS INDEX; CALCIUM, DIETARY; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; LIFE STYLE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATIENT COMPLIANCE; POSTMENOPAUSE; SPAIN; VITAMIN D;

EID: 78649259160     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903452804     Document Type: Article

References (38)

1. National Osteoporosis Foundation 2008. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/Clinicians- Guide.htm
2. Melton LJ 3rd. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7
3. Melton LJ. Epidemiology worldwide. Endocrinol Metab Clin N Am 2003;32:1-13
4. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteporos Int 2000;11:669-74
5. Petrella RJ, Jones TJ. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam Pract 2006;7:31
6. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180:S18
7. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449-58
8. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
9. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density of osteoporosis to prevent fractures: a clinical practice guideline from American College of Physicians. ACP Clinical Practice Guidelines. Ann Intern Med 2008;149:404-15
10. González J, Guañabens N, Gómez C, et al. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de investigación ósea y del metabolismo minireal. Rev Clin Española 2008;208:1-24
11. O'Connell MB. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis. J. Manag Care Pharm 2006;12:S10-19
12. Bruyère O, Malaise O, Neuprez A, et al. Prevalence of vitamin D inadequacy in Europe postmenopausal women. Curr Med Res Opin 2007;23:1939-44
13. Lips P, Hosking D, Lippuner K, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006;260:245-54
14. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-24
15. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986;7:434-49
16. Brown SE. Vitamin D and fracture reduction: and evaluation of the existing research. Alt Med Rev 2008;13:21-33
17. Nieves JW, Komar L, Cosman F, et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nut 1998;67:18-24
18. Koster JC, Hackeng WH, Mulder H. Disminished effect of ethindronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996;51:145-7
19. Nordin B E C. Calcium and osteoporosis. Nutrition 1997;13:664-86
20. Dawson-Hughes B, Dallal GE, Krall EA, et al. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Ann Intern Med 1991;115:505-12
21. Boonen S, Vanderschueren D, Haentjens P, et al. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med 2006;259:539-52
22. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83
23. Tang BM, Eslick GD, Nowson GD, et al. Use of calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years or older: a meta-analysis. Lancet 2007;370:657-66
24. Zhu K, Devine A, Dick IM, et al. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analyzes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab 2008;93:743-9
25. Rossini M, Bianchi G, Di Mundo O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
26. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
27. Penning-van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteporos Int 2008;19:511-17
28. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-18
29. Val Jiménez A, Amorós G, Martínez P, et al. Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del test de Morisky-Green. Aten Primaria 1992;10:767-70
30. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52
31. International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don't continue with treatment. www.osteofound.org
32. Nielsen D, Ryg J, Nissen N, et al. Multidisciplinary patient education in groups increases knowledge on osteoporosis: a randomized controlled trail. Scand J Public Health 2008;36:346-52
33. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. onceweekly alendronate: results from the PERSIST study. Int J Clin Prac 2006;60:869-905
34. Cuddihy MT, Amadio PC, Gabriel SE, et al. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int 2004;15:695-700
35. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
36. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment on postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
37. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009; Jun. 5. Epub ahead print
38. Phinney KW, Sander KE, Sharpless EC, et al. NIST develops serum-based standard reference materials to assess nutritional status. Chemical Science and Technology Laboratory, National Institute of Standards and Technology Food and Nutrition http://www.cstl.nist.gov/projects/fy06/food0683904.pdf